A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Hafnium oxide (Primary) ; Cisplatin
- Indications Carcinoma; Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PharmaEngine
- 07 Jun 2022 Results assessing the feasibility and the recommended phase 2 dose (RP2D) of PEP503 intratumoral injection when added with low-dose (LD) weekly cisplatin-containing chemoradiation (CCRT) in HNSCC presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2022 Results presented in a Nanobiotix media release.
- 05 Jun 2022 According to Nanobiotix media release, data from the study were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.